News &amp; Updates

The duration of exclusive or any breastfeeding does not appear to influence the risk of inflammatory bowel disease (IBD) in infants, according to a study.

Breastfeeding duration has no bearing on IBD risk in offspring

Ceftobiprole as good as daptomycin in achieving S. aureus bloodstream clearance

13 May 2024 by

Ceftobiprole was as effective as daptomycin in achieving bloodstream clearance in patients with complicated Staphylococcus aureus (S. aureus) bacteremia, according to the ERADICATE study presented at ESCMID 2024.

Ceftobiprole as good as daptomycin in achieving S. aureus bloodstream clearance

Aztreonam-avibactam cracks into hard-to-treat MBL-producing MDR-GNB

13 May 2024 by

The fixed-dose combination of aztreonam and avibactam yields a 41.7-percent clinical cure rate in serious infections caused by metallo-β-lactamase (MBL)–producing multidrug-resistant (MDR) Gram-negative bacteria (GNB), according to the results from the phase III ASSEMBLE trial.

Aztreonam-avibactam cracks into hard-to-treat MBL-producing MDR-GNB

Antibiotic ‘breathalyzer’ a promising alternative for therapeutic drug monitoring

12 May 2024 by

Analysis of exhaled breath may be able to identify the presence of specific metabolites for four out of five antibiotics, offering a noninvasive approach to performing therapeutic drug monitoring.

Antibiotic ‘breathalyzer’ a promising alternative for therapeutic drug monitoring

Novel connector improves inhaler delivery in ICU

12 May 2024 by

The new inhaler connector RTC 24-V demonstrates fewer medication errors when compared with the 22M-22F, as shown in a study. Healthcare professionals in the intensive care unit (ICU) also prefer it in terms of safety and accuracy.

Novel connector improves inhaler delivery in ICU

Smartphone-based assessment a reliable tool for evaluating frontotemporal lobar degeneration

Remote evaluation of frontotemporal lobar degeneration (FLTD) with the use of smartphones is feasible and reliable and may help with early detection, as reported in a study.

Smartphone-based assessment a reliable tool for evaluating frontotemporal lobar degeneration

First-in-class oral antibiotic for uncomplicated urogenital gonorrhea clears phase III study

11 May 2024 by

The first-in-class oral bacterial topoisomerase inhibitor zoliflodacin has demonstrated noninferior efficacy versus a combination of ceftriaxone plus azithromycin in the treatment of uncomplicated urogenital gonorrhoea, with favourable safety and tolerability profile.

First-in-class oral antibiotic for uncomplicated urogenital gonorrhea clears phase III study

Psilocybin may help ease depression symptoms

11 May 2024 by

Treatment with psilocybin significantly improves the symptoms of depression, particularly when using self-report scales and when individuals have used psychedelics in the past, results of a systematic review and meta-analysis have shown.

Psilocybin may help ease depression symptoms

11 May 2024

Hormone therapy may boost physical performance in postmenopausal women

Postmenopausal women who are receiving hormone therapy appear to have increased physical performance based on gait speed and timed up-and-go tests, as shown in a cross-sectional study.

Hormone therapy may boost physical performance in postmenopausal women

Zoliflodacin noninferior to dual therapy for uncomplicated urogenital gonorrhoea

11 May 2024 by

Zoliflodacin was noninferior to ceftriaxone plus azithromycin in achieving microbiological cure at the urogenital site in patients with uncomplicated gonorrhoea, according to a study presented at ESCMID 2024.

Zoliflodacin noninferior to dual therapy for uncomplicated urogenital gonorrhoea